Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 or Pembrolizumab + Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous NSCLC
NCT07122687Phase 2Recruiting
- Sponsor
- Innovent Biologics
- Start
- Aug 2025
- Primary completion
- Nov 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI363 in non-small cell lung cancer (NSCLC), sponsored by Innovent Biologics. Started Aug 2025; status: recruiting.
02
Drugs
IBI363
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07122687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07122687.